Human LILRB3 / CD85a / ILT5 Protein, Fc Tag (MALS verified)

Catalog # CDA-H5250

Synonym

LILRB3,CD85a,ILT5

Source

Human LILRB3, Fc Tag(CDA-H5250) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Glu 443 (Accession # AAB68668 (P288R)). Predicted N-terminus: Gly 24

Molecular Characterization

LILRB3(Gly 24 - Glu 443) AAB68668(P288R)	Fc(Pro 100 - Lys 330) P01857

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 72.8 kDa. The protein migrates as 90-115 kDa under reducing (R) condition, and 150 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Human LILRB3, Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS



The purity of Human LILRB3, Fc Tag (Cat. No. CDA-H5250) is more than 90% and the molecular weight of this protein is around 150-185 kDa verified by SEC-MALS.
Report

Background

Leukocyte immunoglobulin-like receptor subfamily B member 3 is also known as LILRB3,ILT-5 or CD85a. LILRB3 plays an role as receptor for class I MHC antigens, which activated upon coligation of LILRB3 and immune receptors, such as FCGR2B and the B-cell receptor. LILRB3 and LILRA6 represent a pair of inhibitory/activating receptors with identical extracellular domains and unknown ligands. LILRB3 can mediate inhibitory signaling via immunoreceptor tyrosine-based inhibition motifs in its cytoplasmic tail whereas LILRA6 can signal through association with an activating adaptor molecule, FcRγ.